Task 13/C26 Challenge Models and Assays to Develop Influenza Vaccines

新发疾病和生物防御的体外和动物模型合同提供了A-C类细菌的抗菌活性测试能力。显示抗菌活性的化合物将接受针对新发和A-C类细菌病原体临床小组的进一步抗菌药敏试验。该合同还提供了小动物和非人类灵长类动物模型的开发和标准化，并可能包括疫苗和/或疗法的功效测试，包括支持产品许可的GLP研究。对小动物有效的疫苗和疗法可在非人类灵长类动物模型中进一步试验。

The In Vitro and Animal Models for Emerging Diseases and Biodefense contract provides antimicrobial activity testing capabilities for Category A-C bacteria. Compounds demonstrating antimicrobial activity will receive further antimicrobial susceptibility testing against clinical panels of emerging and Category A-C bacterial pathogens. This contract also provides the development and standardization of small animal and non-human primate models, and may include efficacy testing of vaccines and/or therapeutics, including GLP studies to support product licensure. Vaccines and therapeutics which are efficacious in small animals may be further tested in non-human primate models.